Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 826 across all filing types
Latest filing 2021-03-18 Earnings Release
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled "ADOCIA annonce ses résultats annuels 2020 et fait un bilan de ses activités" (ADOCIA announces its 2020 annual results and reviews its activities). It contains a detailed table summarizing the consolidated annual accounts (IFRS) for the years ending December 31, 2020, and 2019, including Revenue, Operating Income, Net Result, and Cash Position. The text explicitly discusses the full year's financial performance and operational milestones. This content strongly indicates a formal release of annual financial results. While it is a press release format, the core content is the comprehensive annual financial summary, making it an Earnings Release (ER) or potentially an Annual Report (10-K) if it were the official filing. Given the context of a press release announcing the results and providing key figures, 'ER' (Earnings Release) is the most appropriate classification for this type of announcement, which typically precedes or summarizes the full 10-K filing. Since it covers the full year ('résultats annuels 2020'), it is more substantial than a typical quarterly release, but the format suggests an 'ER' summarizing the year's performance rather than the full statutory 10-K document itself. However, since it explicitly states 'résultats annuels 2020' and provides the full annual financial table, it aligns closely with the function of an Annual Report summary or a very detailed Earnings Release. Given the options, 'ER' covers the announcement of annual results, but '10-K' is for the official yearly report. Since this document is a press release announcing the annual results and providing the key financial tables, 'ER' is the best fit for the announcement itself, although the content relates to the annual period. FY 2020
2021-03-18 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled 'Information relative au nombre d'actions et de droits de vote en date du 28 Février 2021' (Information relative to the number of shares and voting rights as of February 28, 2021). It explicitly states it is published in accordance with the French Commercial Code (Code de Commerce) and AMF regulations (Autorité des Marchés Financiers). The core content is a table detailing the total number of shares and gross/net voting rights as of a specific date. This type of mandatory disclosure regarding the total share capital and voting power is a specific regulatory filing, often related to major shareholding notifications or general capital structure updates, but the most fitting category among the provided options for a routine disclosure of total voting rights is 'Major Shareholding Notification' (MRQ), as these reports often accompany or are related to changes in ownership thresholds, or 'Regulatory Filings' (RNS) if it's a general compliance update. Given the specific nature of reporting total voting rights based on AMF rules, it strongly aligns with the intent of tracking significant ownership changes or capital structure disclosures. However, since it is a direct announcement of the total number of shares and voting rights, and not a change in a specific shareholder's stake (which would be MRQ), it is a fundamental compliance disclosure. If we look closely at the definitions, 'Major Shareholding Notification' (MRQ) is for 'Notification of changes in significant share ownership levels (crossing thresholds)'. This document reports the total count, which is required periodically. Since it is a specific regulatory disclosure that doesn't fit perfectly into the other specific categories (like ER, 10-K, DIV), the most appropriate general regulatory category is RNS. However, the content is highly specific to share count/voting rights. Let's re-evaluate the options. It is not a Director's Dealing (DIRS), nor a Share Issue (SHA) or Transaction in Own Shares (POS). It is a mandatory disclosure of the total voting rights count. In many jurisdictions, this is a specific filing type. Given the options, and its nature as a mandatory regulatory update concerning share capital structure, it is closest to a general regulatory filing (RNS) or potentially a specific capital change announcement (SHA). Since it is a routine update of the total count, not an issuance or repurchase, RNS is the safest fallback for a specific regulatory compliance report not covered elsewhere. Upon review, this type of filing (total share capital and voting rights disclosure) is often grouped under general regulatory announcements when a more specific code like 'Share Capital Update' is missing. I will classify it as RNS, as it is a mandatory regulatory announcement to the AMF.
2021-03-17 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Share Issue/Capital Change Classification · 1% confidence The document explicitly states its purpose: to release the 'Total number of outstanding shares as well as its voting rights as of February 28th, 2021,' citing French regulatory articles (L. 233-8 II of the French « Code de Commerce » and article 223-16 of the AMF charter). This type of mandatory disclosure regarding share capital structure and voting rights is a specific regulatory filing. While it is a formal announcement, it is not a general regulatory filing (RNS) or a major shareholding notification (MRQ) which typically reports changes in ownership thresholds. It is a specific disclosure about the total number of shares and voting rights, which aligns best with the category for Director's Dealing (DIRS) or a specific regulatory disclosure. However, given the options, the content is a direct report of share structure data mandated by regulation, which often falls under specific transaction/holding reports. Since it is not a director's trade (DIRS), a major shareholder crossing a threshold (MRQ), or a general announcement (RNS), and it deals with the fundamental capital structure reporting required by the AMF, it is closest to a specific regulatory disclosure. In many databases, these specific share count disclosures are categorized separately or fall under a general regulatory filing. Given the provided definitions, the closest fit for a mandatory, periodic disclosure about the company's share structure and voting rights, which is not a dividend, capital change, or insider trade, is often grouped with other specific regulatory disclosures. Since the document is a formal press release detailing required regulatory data points (shares outstanding and voting rights), and it is not a general announcement of a report (RPA), it is best classified as a specific regulatory filing. If a more specific code existed for 'Share Capital Disclosure,' that would be ideal. Lacking that, and noting it is a formal disclosure mandated by the AMF, it fits best under the general 'Regulatory Filings' (RNS) as a fallback for specific, non-listed disclosures, or potentially 'Share Issue/Capital Change' (SHA) if interpreted broadly, but SHA usually implies an *action* (issue/split). Since this is a *report* of the current state mandated by law, RNS is the most appropriate general regulatory bucket here, although it is highly specific. Re-evaluating the definitions: It is not a DIV, CAP, SHA, or POS. It is a formal regulatory disclosure. I will classify it as RNS (Regulatory Filings) as the most appropriate general regulatory category for mandatory, non-standard disclosures.
2021-03-17 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release announcing the initiation of a Phase 2 clinical trial for a drug called M1Pram in patients with Type 1 Diabetes. It details the study design, previous results, and provides background on the drug and the company (Adocia). This type of announcement, focusing on clinical trial progress and scientific updates, is characteristic of an Earnings Release (ER) if it were summarizing financial results, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, given the content is a detailed update on clinical development, it most closely aligns with an Earnings Release (ER) which often includes operational highlights alongside financial summaries, or an Investor Presentation (IP) if it were structured as slides. Since this is a formal announcement of operational progress (clinical trial initiation) and includes forward-looking statements typical of such releases, and it is not a full financial report (10-K, IR) or a transcript (CT), the best fit among the provided options for a major operational/clinical update announcement is Earnings Release (ER), as these often serve as the primary vehicle for such news, even if financial figures are minimal or absent. If the document were purely scientific without the context of a reporting period, it might lean towards RNS, but the structure suggests a standard corporate update release.
2021-03-10 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release written in French announcing the initiation of a Phase 2 clinical study for a drug candidate named M1Pram for Type 1 diabetes. It details the study design, primary endpoints (weight loss, HbA1c improvement), comparison to existing treatments (insulin lispro), and references prior Phase 1 results. This content structure—announcing a significant operational/clinical development milestone—is characteristic of an Earnings Release (ER) or a general press release related to company operations. Since it is not a full annual report (10-K), a formal audit report (AR), a management discussion/analysis (MDA), or a transcript (CT), and it focuses on immediate operational news rather than just a notice of a future report (RPA), the most fitting category for a company's primary operational update/announcement is 'Earnings Release' (ER), as these often contain key operational highlights alongside financial context, or 'Regulatory Filings' (RNS) if it were purely regulatory. Given the focus on clinical trial initiation and results summary, it functions as a major operational update. However, in the context of standard financial filings, announcements of clinical trial progress are often categorized broadly. Since it is a detailed announcement of a major development, and not just a brief financial summary, 'ER' (Earnings Release, often used for major operational news releases) is a strong candidate, but 'RNS' (Regulatory Filings/General Announcement) is the safest fallback for non-standard, non-financial-statement press releases. Given the detailed nature of the clinical update, it functions as a significant corporate announcement. If the company had provided financial results, ER would be certain. Since it is a major operational update, I will classify it as a general Regulatory Filing/Announcement (RNS) as it doesn't fit the specific financial report types, but it is a formal communication to the market.
2021-03-10 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 1% confidence The document is titled "ADOCIA : Information relative au nombre d'actions et de droits de vote en date du 31 janvier 2021" and explicitly states it is published in accordance with French commercial code and AMF (Autorité des Marchés Financiers) regulations to report the number of shares and voting rights as of a specific date (January 31, 2021). This type of periodic disclosure regarding capital structure and voting rights is a standard regulatory filing requirement, often related to major shareholding thresholds or general corporate updates. Since it is a specific regulatory disclosure about share capital/voting rights and not a full financial report (10-K, IR) or a management change (MANG), the most fitting category is a general Regulatory Filing (RNS), as it is a specific, mandated disclosure that doesn't fit the other specialized categories like Director's Dealing (DIRS) or Major Shareholding Notification (MRQ), although it is related to share structure. Given the context of French regulatory reporting (AMF), RNS serves as the best general regulatory announcement category when a more specific code like MRQ (which usually reports *changes* crossing a threshold) is not perfectly applicable to a static monthly count, or if it's not explicitly a Director's Dealing (DIRS). However, upon re-evaluation, this specific report on the total number of shares and voting rights is a very common type of disclosure that often falls under general regulatory announcements. Since it is a formal, periodic regulatory update mandated by the AMF, RNS is appropriate as a catch-all for specific regulatory disclosures not covered elsewhere. It is not an Earnings Release (ER), Interim Report (IR), or a proxy statement (PSI).
2021-02-16 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.